WO2000035428A3 - Tricyclische stickstoffheterocyclen als pde iv inhibitoren - Google Patents

Tricyclische stickstoffheterocyclen als pde iv inhibitoren Download PDF

Info

Publication number
WO2000035428A3
WO2000035428A3 PCT/EP1999/009086 EP9909086W WO0035428A3 WO 2000035428 A3 WO2000035428 A3 WO 2000035428A3 EP 9909086 W EP9909086 W EP 9909086W WO 0035428 A3 WO0035428 A3 WO 0035428A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde
inhibitors
nitrogen heterocycles
tricyclic nitrogen
tricyclic
Prior art date
Application number
PCT/EP1999/009086
Other languages
English (en)
French (fr)
Other versions
WO2000035428A2 (de
Inventor
Matthias Hoffmann
Birgit Jung
Ulrike Kuefner-Muehl
Christopher John Montagu Meade
Original Assignee
Boehringer Ingelheim Pharma
Matthias Hoffmann
Birgit Jung
Kuefner Muehl Ulrike
Christopher John Montagu Meade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Matthias Hoffmann, Birgit Jung, Kuefner Muehl Ulrike, Christopher John Montagu Meade filed Critical Boehringer Ingelheim Pharma
Priority to CA002345752A priority Critical patent/CA2345752A1/en
Priority to EP99959324A priority patent/EP1140098A2/de
Priority to JP2000587749A priority patent/JP2002532411A/ja
Publication of WO2000035428A2 publication Critical patent/WO2000035428A2/de
Publication of WO2000035428A3 publication Critical patent/WO2000035428A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung tricyclischer Stickstoffheterocyclen der allgemeinen Formel (I) als Arzneimittel mit PDE IV inhibierender Wirkung, wobei die Reste R?1, R2 und R3¿ die in der Beschreibung und die in den Ansprüchen angegebene Bedeutung aufweisen.
PCT/EP1999/009086 1998-12-17 1999-11-24 Tricyclische stickstoffheterocyclen als pde iv inhibitoren WO2000035428A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002345752A CA2345752A1 (en) 1998-12-17 1999-11-24 Tricyclic nitrogen heterocycles as pde iv inhibitors
EP99959324A EP1140098A2 (de) 1998-12-17 1999-11-24 Tricyclische stickstoffheterocyclen als pde iv inhibitoren
JP2000587749A JP2002532411A (ja) 1998-12-17 1999-11-24 Ｐｄｅｉｖ抑制剤としての三環窒素複素環化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858331A DE19858331A1 (de) 1998-12-17 1998-12-17 Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren
DE19858331.1 1998-12-17

Publications (2)

Publication Number Publication Date
WO2000035428A2 WO2000035428A2 (de) 2000-06-22
WO2000035428A3 true WO2000035428A3 (de) 2000-09-28

Family

ID=7891477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009086 WO2000035428A2 (de) 1998-12-17 1999-11-24 Tricyclische stickstoffheterocyclen als pde iv inhibitoren

Country Status (5)

Country Link
EP (1) EP1140098A2 (de)
JP (1) JP2002532411A (de)
CA (1) CA2345752A1 (de)
DE (1) DE19858331A1 (de)
WO (1) WO2000035428A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
WO2006075748A1 (ja) * 2005-01-17 2006-07-20 Santen Pharmaceutical Co., Ltd. アレルギー性結膜疾患治療剤
WO2008103357A1 (en) * 2007-02-21 2008-08-28 E. I. Du Pont De Nemours And Company Fungicidal tricyclic 1,2,4-triazoles
TWI609870B (zh) * 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
WO1999065912A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidine als arzneimittel mit adenosinantagonistischer wirkung
WO2000012511A1 (de) * 1998-08-27 2000-03-09 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
WO1999065912A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidine als arzneimittel mit adenosinantagonistischer wirkung
WO2000012511A1 (de) * 1998-08-27 2000-03-09 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
U SCHRÄPLER ET AL: "Die Synthese von cyclischen Acyloinen aus Dicarbonsäureestern durch Darstellung und Hydrolyse der Bis-trimethylsiloxy-cycloalkene", CHEMISCHE BERICHTE,DE,VERLAG CHEMIE GMBH. WEINHEIM, vol. 97, no. 97, 1964, pages 1373 - 1382-1383, XP002101359, ISSN: 0009-2940 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Also Published As

Publication number Publication date
EP1140098A2 (de) 2001-10-10
CA2345752A1 (en) 2000-06-22
WO2000035428A2 (de) 2000-06-22
JP2002532411A (ja) 2002-10-02
DE19858331A1 (de) 2000-06-21

Similar Documents

Publication Publication Date Title
WO2000076971A3 (en) Serine protease inhibitors
WO2000076970A3 (en) Serine protease inhibitors
WO2002032898A3 (de) Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
EP1270557A4 (de) Ethylendiamin-derivate
WO2002059083A3 (en) Novel compounds
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
WO1999050255A3 (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
EP0661284A4 (de) Thienodiazepinverbindung und ihre medizinische verwendung.
WO2002094020A8 (de) Verwendung von triazolopyrimidin-derivaten als mikrobizide im materialschutz
WO2004018465A3 (en) Benzonaphthyridines with pde 3/4 inhibiting activity
AU5554198A (en) 3-thiocarbamoylpyrazole derivatives as pesticides
WO1999041237A8 (en) Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
GEP20084539B (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
EP0772590A1 (de) Thrombin-inhibitoren
BG104812A (en) New dihydropyrimidines
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
AU2002257587A1 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
HUP0400782A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
BG105715A (en) Combination chemotherapy
AU4205197A (en) New thiazole derivatives with phosphodiesterase-inhibiting effect
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
WO2000035428A3 (de) Tricyclische stickstoffheterocyclen als pde iv inhibitoren
WO2002014313A3 (de) Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999959324

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2345752

Country of ref document: CA

Ref country code: CA

Ref document number: 2345752

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005936

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 587749

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999959324

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999959324

Country of ref document: EP